What happened
In March 2026, the story went viral: Sydney tech entrepreneur Paul Conyngham used ChatGPT and AlphaFold to design a personalized mRNA cancer vaccine for his rescue dog Rosie after conventional treatments failed. He spent $3,000 on genome sequencing at the University of New South Wales, used AI tools to identify tumor mutations, and worked with UNSW researchers to produce the vaccine. Within weeks of treatment in December 2025, Rosie's tumors shrank by 75%. Sam Altman called it an "amazing story." Now it's a company.
The details
Gamgee, backed by Y Combinator's Summer 2026 batch, is building an end-to-end platform for personalized mRNA cancer vaccines for dogs. The company sequences a dog's tumor and healthy DNA, identifies cancer-specific mutations, and designs a custom vaccine. Gamgee is running clinical trials in Australia and accepting cases globally. The company manages intake, sequencing, vaccine design, manufacturing, treatment, and monitoring—all in-house.
Why it matters
Conyngham's original pipeline was sovereign: he paid for sequencing, used open tools like AlphaFold, and collaborated with university researchers. He owned the process. Gamgee-as-a-company flips that. Pet owners submit cases; Gamgee controls the science. It's faster, more accessible, and fully verticalized. It's also the familiar pattern: a proof-of-concept built on open tools becomes a service you can't replicate. You get the outcome. They get the capability. The hope is that the learning feeds forward into human medicine—and that someone, somewhere, keeps the tools open enough to let the next Paul just do it himself.